Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work
Spurred by an apparent shift towards a more pro-business stance among government ministers, a number of top pharmaceutical executives and heads of UK industry bodies have publicly called for some form of regulatory alignment deal between the UK and the EU after Brexit.
You may also be interested in...
Brexit: Bids In For The EMA As Portugal Drops Lisbon For Porto, Bratislava Emerges As Possible Front-Runner
All bids to host the European Medicines Agency were to have been in by close of business on July 31. Portugal has unexpectedly switched its candidacy from Lisbon to Porto, Bratislava could emerge as a surprise favorite. Meanwhile the CEO of AstraZeneca has said investment decisions are being put on hold pending more clarity over Brexit.
The EMA has given some details of its business continuity plan for Brexit preparedness, which includes diverting some resources from lower-priority tasks to focus on core activities.
Pressure from industry and other bodies seems to be paying off after two senior government ministers publicly called for a “close working relationship” between the UK and the EU after Brexit. The move has been welcomed by the life sciences industry, which has been lobbying for some sort of regulatory cooperation agreement to avoid regulatory divergence and possible delays to new product launches.